ReviewClinical endocrinology2021
Clinical and biochemical discriminants between functional hypothalamic amenorrhoea (FHA) and polycystic ovary syndrome (PCOS).
Review in Clinical endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05410886 (A Questionnaire-based Study to Improve the Diagnosis of Functional Hypothalamic Amenorrhea), which is not on this map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Questionnaire-based Study to Improve the Diagnosis of Functional Hypothalamic Amenorrhea (FHA) in Women With Secondary Amenorrhea Attending Hospital
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Pharmacological interventions to improve bone density in functional hypothalamic amenorrhea: a systematic review and network meta-analysis of randomized clinical trials.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- [Difficulties of differential diagnosis of functional hypothalamic amenorrhea and polycystic ovary syndrome: a systematic review].Problemy endokrinologii · 2024Pooled it
- Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial.Human reproduction (Oxford, England) · 2026Trial
- Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea.The Journal of clinical endocrinology and metabolism · 2023Trial
- Functional hypothalamic amenorrhea and anti-Müllerian hormone: insights for fertility assessment.Journal of endocrinological investigation · 2026Article
- Article
- Psychological stress and functional ovarian suppression in women with PCOM: an observational study of FHA-like neuroendocrine phenotypes.Archives of women's mental health · 2026Observational
- Considerations of Fertility in Elite Sportswomen: A Narrative Review.BJOG : an international journal of obstetrics and gynaecology · 2026Review
- AMH in PCOS and Beyond-Rare Case Series.Diagnostics (Basel, Switzerland) · 2026Article
- Distinguishing Polycystic Ovary Syndrome Phenotype D from Functional Hypothalamic Amenorrhea with Polycystic Ovarian Morphology: Clinical and Hormonal Insights from a Pilot Retrospective Study.Journal of menopausal medicine · 2025Article
- Changes in anti-mullerian hormone levels after recovery from functional hypothalamic amenorrhea: a retrospective cohort study about women with and without polycystic ovarian morphology.Reproductive biology and endocrinology : RB&E · 2025Article
- Beyond ovarian Morphology: Integrative stress profiling for distinguishing polycystic ovary syndrome from functional hypothalamic amenorrhea.Comprehensive psychoneuroendocrinology · 2025Article
- Kisspeptin and neurokinin B: roles in reproductive health.Physiological reviews · 2025Review
- Probiotics ameliorates hypothalamic amenorrhea in a rat model of PCOS.Metabolic brain disease · 2025Article
- Article
- Functional hypothalamic amenorrhoea and polycystic ovarian morphology: a narrative review about an intriguing association.Human reproduction update · 2025Review
- Identifying nutraceutical targets to treat polycystic ovary syndrome using graph representation learning.npj women's health · 2025Article
- Neuroendocrine disturbances in women with functional hypothalamic amenorrhea: an update and future directions.Endocrine · 2024Review
- Irregular Cycles, Ovulatory Disorders, and Cardiometabolic Conditions in a US-Based Digital Cohort.JAMA network open · 2024Article
- Obesity-Related Hypogonadism in Women.Endocrine reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSecondary oligo/amenorrhoea occurs in 3%-5% of women of reproductive age. The two most common causes are polycystic ovary syndrome (PCOS) (2%-13%) and functional hypothalamic amenorrhoea (FHA) (1%-2%). Whilst both conditions have distinct pathophysiology and their diagnosis is supported by guidelines, in practice, differentiating these two common causes of menstrual disturbance is challenging. Moreover, both diagnoses are qualified by the need to first exclude other causes of menstrual disturbance.
aimTo review clinical, biochemical and radiological parameters that could aid the clinician in distinguishing PCOS and FHA as a cause of menstrual disturbance.
resultsFHA is uncommon in women with BMI > 24 kg/m
conclusionFurther data directly comparing the discriminatory potential of these markers to differentiate PCOS and FHA in women with secondary amenorrhoea would be of value in defining an objective probability for PCOS or FHA diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.